KUROS BIOSCIENCES BV

Their core work

Kuros Biosciences is a Dutch biotech SME specializing in bone regeneration and advanced biomaterial scaffolds for orthopedic and tissue repair applications. They develop 3D-printed and biofabricated matrices that promote bone growth, combining gene therapy approaches with additive manufacturing to create implantable products. Their work spans from fast bone growth solutions (their CHARME project) to RNA-based bone regenerative therapies and multi-tissue interface repair using human platelet lysate-based scaffolds.

What they specialise in

How they've shifted over time

Early work (2015-2017) focused on cost-effective bone growth manufacturing (CHARME) and cell therapy for urinary continence (MUSIC), reflecting a broader regenerative medicine scope. From 2020 onward, the company narrowed sharply toward advanced scaffold fabrication — 3D printing, gene-activated matrices, electrospinning, and platelet-based biomaterials — all applied specifically to bone and multi-tissue repair. The shift shows a clear move from general regenerative medicine toward becoming a specialist in biofabricated implantable scaffolds.

Kuros is converging on the intersection of additive manufacturing and biological therapeutics for bone repair, positioning itself as a scaffold and biomaterial supplier for next-generation orthopedic treatments.

How they like to work

Kuros coordinated one project (CHARME, their largest by funding) but predominantly joins as a participant, contributing specialized biomaterial and manufacturing expertise to larger consortia. With 25 unique partners across 9 countries in just 4 projects, they work in moderately sized, internationally diverse teams rather than repeating with the same partners. This suggests they are sought after for their specific technical capabilities rather than building long-term consortium clusters.

Kuros has collaborated with 25 distinct partners across 9 European countries through 4 projects, showing a wide network relative to their project count. Their partnerships span both health and manufacturing sectors, indicating cross-disciplinary reach in the tissue engineering space.

What sets them apart

Kuros sits at a rare intersection: they are a commercial SME with hands-on manufacturing capability (3D printing, electrospinning) combined with deep knowledge of biological therapeutics (gene therapy, platelet lysates, cell-based approaches). Unlike academic labs that develop concepts, Kuros brings a product-oriented mindset — their CHARME project explicitly targeted "fast and cost-effective" bone growth. For consortium builders, they offer the kind of translational bridge between lab research and manufacturable medical products that reviewers look for.

Highlights from their portfolio

• CHARME
  Their only coordinated project and largest funding (EUR 1.84M), focused on cost-effective bone growth manufacturing — signals their core commercial ambition.
• cmRNAbone
  Combines gene therapy (chemically modified RNA) with 3D printing for bone regeneration — a technically ambitious convergence of biologics and digital fabrication.
• InterLynk
  Their most recent project (2021-2025) exploring multi-tissue interface repair with platelet-based scaffolds, showing their latest strategic direction.